|
Name |
Laccaic acid D
|
Molecular Formula | C16H10O7 | |
IUPAC Name* |
3,6,8-trihydroxy-1-methyl-9,10-dioxoanthracene-2-carboxylic acid
|
|
SMILES |
CC1=C2C(=CC(=C1C(=O)O)O)C(=O)C3=C(C2=O)C(=CC(=C3)O)O
|
|
InChI |
InChI=1S/C16H10O7/c1-5-11-8(4-10(19)12(5)16(22)23)14(20)7-2-6(17)3-9(18)13(7)15(11)21/h2-4,17-19H,1H3,(H,22,23)
|
|
InChIKey |
DDTNCHWMNZLWKO-UHFFFAOYSA-N
|
|
Synonyms |
Laccaic acid D; Flavokermesic acid; Xanthokermesic acid; 18499-84-8; 3,6,8-trihydroxy-1-methyl-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid; SCHEMBL2138871; CHEBI:90194; DTXSID501316089; Q27162392; 1-methyl-3,6,8-trihydroxy-anthraquinone-2-carboxylic acid; 3,6,8-trihydroxy-1-methyl-9,10-dioxoanthracene-2-carboxylic acid; 9,10-Dihydro-3,6,8-trihydroxy-1-methyl-9,10-dioxo-2-anthracenecarboxylic acid; 9,10-Dihydro-3,6,8-trihydroxy-1-methyl-9,10-dioxo-2-anthracenecarboxylic acid, 9CI
|
|
CAS | 18499-84-8 | |
PubChem CID | 9883304 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 314.25 | ALogp: | 2.8 |
HBD: | 4 | HBA: | 7 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 132.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 23 | QED Weighted: | 0.541 |
Caco-2 Permeability: | -5.857 | MDCK Permeability: | 0.00000557 |
Pgp-inhibitor: | 0.006 | Pgp-substrate: | 0.016 |
Human Intestinal Absorption (HIA): | 0.12 | 20% Bioavailability (F20%): | 0.173 |
30% Bioavailability (F30%): | 1 |
Blood-Brain-Barrier Penetration (BBB): | 0.02 | Plasma Protein Binding (PPB): | 98.81% |
Volume Distribution (VD): | 0.472 | Fu: | 2.90% |
CYP1A2-inhibitor: | 0.432 | CYP1A2-substrate: | 0.082 |
CYP2C19-inhibitor: | 0.028 | CYP2C19-substrate: | 0.04 |
CYP2C9-inhibitor: | 0.453 | CYP2C9-substrate: | 0.063 |
CYP2D6-inhibitor: | 0.048 | CYP2D6-substrate: | 0.106 |
CYP3A4-inhibitor: | 0.238 | CYP3A4-substrate: | 0.053 |
Clearance (CL): | 2.722 | Half-life (T1/2): | 0.601 |
hERG Blockers: | 0.023 | Human Hepatotoxicity (H-HT): | 0.304 |
Drug-inuced Liver Injury (DILI): | 0.988 | AMES Toxicity: | 0.643 |
Rat Oral Acute Toxicity: | 0.018 | Maximum Recommended Daily Dose: | 0.098 |
Skin Sensitization: | 0.423 | Carcinogencity: | 0.065 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.745 |
Respiratory Toxicity: | 0.093 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000935 | 0.794 | D0N1FS | 0.340 | ||||
ENC000094 | 0.667 | D0K8KX | 0.330 | ||||
ENC000571 | 0.654 | D07MGA | 0.326 | ||||
ENC002067 | 0.646 | D04AIT | 0.322 | ||||
ENC005279 | 0.641 | D0AZ8C | 0.272 | ||||
ENC000335 | 0.625 | D0H1AR | 0.272 | ||||
ENC002296 | 0.620 | D07JHH | 0.267 | ||||
ENC001058 | 0.616 | D01XDL | 0.262 | ||||
ENC002031 | 0.573 | D01XWG | 0.262 | ||||
ENC000939 | 0.553 | D00KRE | 0.260 |